Fig. 5.

(a) Anti-Apo2L/TRAIL mAb inhibits DEN-2-induced cytotoxicity. HepG2 cells were pretreated for 2 h with anti-Apo2L/TRAIL mAb (10 μg ml⁻¹) or control IgG₁ (10 μg ml⁻¹) before being infected with DEN-2 (m.o.i. of 8). After infection, cells were incubated in medium containing antibody (DEN-2+Apo2L/TRAIL mAb) or control IgG₁ (DEN-2) for 72 h before the percentage of surviving cells was determined. C6/36 sup, mock-infected control. (b) Cell-surface expression of Apo2L/TRAIL receptors on HepG2 cells. HepG2 cells were stained with control mouse IgG₁ or anti-human DR4/TRAIL-R1, DR5/TRAIL-R2, DcR1/TRAIL-R3 or DcR2/TRAIL-R4 mAb and analysed by flow cytometry. Shaded and open peaks correspond to specific and control staining, respectively. The x- and y-axes indicate the fluorescence intensity and relative number of cells, respectively.